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Abstract
The aim of this study was to assess community pharmacists’ (CPs) perceptions toward mental healthcare, and the barriers 
faced in providing pharmaceutical care (PC) services to these patients. A 40-item survey was posted to CPs. Ninety-six phar-
macists participated. The majority (84.2%) agreed there is a role for CPs to play in mental health care, while approximately 
60% agreed it is their responsibility to provide PC to these patients. The biggest barrier to providing this service is the lack 
of knowledge, cited by close to 50% of respondents. This corresponds with the revelation that close to 60% believe that they 
have a poor or fair understanding of mental disorders. About 30% of respondents said they do not stock psychotropic drugs 
at all, mainly due to medico-legal reasons, and low prescription requests. Our findings highlight the need for more training 
of CPs in managing patients with mental disorders.
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Introduction
Mental disorders are among the strongest predictors of sui-
cide, with more than 80% of patients committing suicide 
due to being untreated at the time of their death (Nock et al. 
2009). Life expectancy rates of those with mental disorders 
are also 15 to 20 years less than the general population, often 
due to an increased risk in premature death (NHS England 
2016). Nonadherence to medication among patients with 
mental disorders is reported to be more than 50% (Horne 
et al. 2009; Lacro et al. 2002; Lieberman et al. 2005), and 
leads to significantly negative clinical and economic con-
sequences in these patients (Higashi et al. 2013; Ho et al. 
2015). With the move towards deinstitutionalizing mental 
health care and encouraging management in the commu-
nity setting, community pharmacists (CPs) can play a big-
ger role by providing pharmaceutical care (PC) services. A 
systematic review found that PC services by CPs resulted in 
improved adherence, and reduced the number of inappropri-
ate medications prescribed in patients with mental disorders 
(Bell et al. 2005).
In Malaysia, a national survey revealed that 12% of adults 
suffer from some form of mental illness (Ministry of Health 
2011), an increase from 10% in 1996 (Ministry of Health 
1996). In the face of high costs of medications and budget 
cuts, restricted access to psychotropic medications could 
harm patients and result in poor treatment outcomes (Koy-
anagi et al. 2005). With the increasing prevalence of mental 
health disorders, there will be an increase in demand for psy-
chotropics as well as pharmacists who are able to provide PC 
services to this group of patients. Community pharmacies 
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can thus play an important role in ensuring patients have an 
interrupted supply of regular medications as they are highly 
accessible with extended opening hours.
Patients, however, have reported feeling stigmatized by 
healthcare professionals, encountering rejection and dis-
crimination when seeking treatment (Knox et al. 2014). 
Studies have also found that CPs have a stigmatizing attitude 
toward patients with mental disorders (Liekens et al. 2012a, 
b). This is a profound scenario in Malaysia, with patients 
with schizophrenia, bipolar disorder, and major depressive 
disorder (MDD) stigmatized and discriminated the most by 
healthcare professionals (Hanafiah and Van Bortel 2015). 
Stigma is closely related to religion and culture, and has a 
strong influence on the views of healthcare professionals 
when dealing with these disorders and patients (Office of the 
Surgeon General (US), Center for Mental Health Services 
(US), and National Institute of Mental Health (US) 2001). In 
light of the cultural diversity in this country, which is made 
up of Malays (60%), Chinese (> 20%), Indians (~ 10%), and 
other native ethnic groups, we conducted this study to ascer-
tain the perceptions of CPs and the barriers faced in provid-
ing PC services to patients with mental disorders.
Methods
This was a cross-sectional study involving CPs in Malaysia. 
A list of 926 pharmacies registered in Peninsular Malaysia 
was obtained from the Malaysian Pharmaceutical Society 
website. Assuming an overestimated response distribution 
of 50%, a minimum effective sample size of 88 was needed 
to achieve a confidence interval of 95% and a 10% margin of 
error (Raosoft 2004). Taking into account the low response 
rate of surveys, 300 pharmacies were randomly selected. 
Asurvey containing a cover letter inviting pharmacists to 
take part in the study and a pre-paid return envelope was 
mailed to those community pharmacies. No financial incen-
tives were offered, and no reminders were sent.
Study Instrument
The survey form was a 40-item questionnaire consisting 
of both open-ended and close-ended questions. Some of 
these responses were rated on a 5-point Likert scale ranging 
from 1 (strongly disagree) to 5 (strongly agree). The fol-
lowing areas were included: perception of pharmacists on 
patients and mental disorders, knowledge on mental health, 
the level of comfort regarding their level of confidence and 
responsibilities managing mental disorders, PC services pro-
vided (including types of psychotropics stocked and pre-
scription for psychotropics), reasons for not stocking, and 
barriers to providing PC services. Demographics such as 
qualifications and work experience were also obtained from 
all respondents.
The survey was developed based on the study objectives 
as well as a review of the literature, and 10 experts in the 
fields of mental health as well as PC performed face and 
content validation. The survey was pilot-tested on five phar-
macists to assess their comprehension of the survey, and the 
time taken to complete it. The survey took approximately 
20–30 min to complete, and was available in English. This 
study was approved by the University Ethics Committee. 
There are no known conflicts of interest, and all authors 
certify responsibility for the manuscript.
Data Analysis
Baseline demographic data were presented using descriptive 
statistics. Continuous variables were expressed by means 
and standard deviations, whereas categorical/nominal data 
were presented using frequency and percentage. Content 
analysis was performed on the open-ended comments. 
To create a composite picture on what respondents disa-
greed and agreed on for questions employing the 5-point 
Likert scale responses, the scores for the first two columns 
(“strongly disagree” and “disagree”) were added up to show 
what they disagreed on, while the scores for the last two 
columns (“agree” and “strongly agree”) were totaled up to 
show what they agreed on. Likert-scale responses for (1) the 
perception of pharmacists with regard to mental illness and 
patients with mental disorders, and (2) the level of comfort 
of pharmacists in managing mental disorders were also tabu-
lated as means, and totaled to give an overall picture. The 
level of comfort of pharmacists encompassed the responses 
of pharmacists in reference to their level of confidence and 
responsibility with regard to managing mental disorders.
General linear regression was employed to examine pre-
dictors of perceptions and level of comfort of pharmacists, 
and the following independent variables were included in 
the models: age, gender, type of pharmacy, knowledge level, 
personal and family history of mental disorders, years since 
graduation, postgraduate qualifications, work experience in 
community and hospital pharmacies, and belief if personal 
opinion about mental illness will affect their ability to pro-
vide PC to patients. Dummy variables were created for cat-
egorical variables with more than two outcomes. Variance 
inflation factor values were inspected for the possibility of 
multicollinearity, with results higher than 10 being consid-
ered as indicative of this problem. The a priori level of sig-
nificance was 0.05, and all analyses were performed using 
Microsoft Excel and SPSS 24.0 statistical software (SPSS, 
Inc., Chicago, IL, USA).
To determine the potential barriers in providing PC, the 
relative importance weight factor (RIWF) was calculated for 
each of the 16 barriers identified to determine the top three 
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barriers, with the value closest to ‘1’ signifying the main 
barrier. Calculation of the RIWF was done according to the 
following equation:
 where W is the weight given to each factor by the respond-
ents and ranges from 1 to 5 (where ‘1’ is ‘strongly disagree’ 
and ‘5’ is ‘strongly agree’), A is the highest weight i.e. 5, and 
N is the total number of respondents (Gündüz et al. 2013).
Results
Demographics of Respondents
Of the 300 pharmacies, 96 pharmacists responded to the 
survey, while 39 envelopes were returned because the prem-
ises were no longer in business. There was a slight female 
preponderance (52.1%). Most of the respondents had under-
graduate-level education (70.8%), and less than 5 years of 
working experience in a community pharmacy (42.7%) or 
hospital (67.7%). None of the respondents believed they pos-
sessed excellent knowledge of mental disorders (Table 1). 
The majority agreed that the main reasons for selecting 
‘Poor’ or ‘Fair’ knowledge were ‘inadequate training in 
this field’ (93%), and ‘few prescriptions for psychotropics’ 
(87.3%). Others included ‘inadequate material on men-
tal health therapy’ (54.5%), ‘inadequate education during 
undergraduate on mental disorders’ (52.6%), ‘perceive 
mental disorders as a difficult area or specialty compared 
to cardiovascular and endocrine disorders such as diabetes’ 
(51.8%), and ‘lack of interest’ (26.8%).
Stocking and Pharmaceutical Care Services
Thirty-one (32.3%) pharmacists did not stock any psycho-
tropics at all, and 40% of these referred patients with mental 
disorders to hospitals, followed by private clinics (27.1%), 
and other community pharmacies (15.6%). Reasons for not 
stocking were strict regulations of record keeping as required 
by law (72.4%), numerous medical legal issues (69%), and 
that they only received few prescription requests (60.7%) 
(Table 2). The maximum number of psychotropics stocked 
was 29, as reported by 2 (2.1%) pharmacists, and antidepres-
sants were the class of psychotropics most stocked (48.7%). 
Of those who stocked psychotropics, the majority stocked 
carbamazepine (70.8%), followed by amitriptyline and esci-
talopram (64.6% respectively), and valproic acid (56.9%) 
(Table 3). Prescriptions for psychotropics were most fre-
quently for sleep-related disorders (37.5%), followed by 
depression (21.9%) and anxiety (18.8%). Prescribers were 
generally evenly spread between general practitioners 
RIWF =
훴W (0 ≤ RIWF ≤ 1)
A × N
,
(27.1%), and specialists from both government (28.1%) and 
private (29.2%) hospitals/institutions.
The majority (84.2%) of respondents agreed that there 
is a role for CPs to play in mental health care, while 61.7% 
agreed it is their responsibility to provide PC to patients 
with mental disorders. However, 66% agreed that only phar-
macists with knowledge and training in mental health care 
should handle such patients. Counseling was the main PC 
service provided, as reported by 60.4% of respondents. The 
majority of respondents, however, reported low frequencies 
Table 1  Characteristics of respondents (n = 96)
SD standard deviation
Characteristics N (%)
Age, years (mean ± SD) 35.33 ± 12.94
Ethnicity
 Malay 19 (19.8)
 Chinese 67 (69.8)
 Indian 9 (9.4)
 Other 1 (1.0)
Years after graduation (basic degree) (n = 95)
 < 5 years 29 (30.5)
 5–10 years 19 (20.0)
 > 10 years 47 (49.5)
Role in pharmacy
 Owner 23 (24.0)
 Manager 12 (12.5)
 Full time pharmacist 39 (40.6)
 Locum pharmacist 27 (28.5)
Type of pharmacy (n = 94)
 Chain 33 (35.1)
 Independent 61 (64.9)
Personal history of mental illness
 Yes 3 (3.1)
 No 88 (91.7)
 Preferred not to answer 5 (5.2)
History of mental illness in a family member/close friend
 Yes 25 (26.0)
 No 64 (66.7)
 Preferred not to answer 7 (7.3)
Knowledge level on mental disorders
 Good 34 (37.4)
 Fair 49 (53.8)
 Poor 8 (98.8)
Belief that own opinions and beliefs about mental disorders would 
affect their ability to provide PC to these patients
 Definitely 20 (20.8)
 Probably 27 (28.1)
 Maybe 23 (24.0)
 Not at all 18 (18.8)
 Don’t know 8 (8.3)
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of providing PC services, with less than 20% monitoring for 
efficacy, side effects, and adherence (Table 3).
Perception and Level of Comfort of Pharmacists 
in Managing Mental Disorders
While 80% agreed that mental illness is nothing to be 
ashamed of, respondents were overall neutral with regard 
to their perception of patients with mental disorders, and 
of mental illness (Table 4). A general linear regression was 
calculated to predict the perception of pharmacists based on 
the independent variables. The model reasonably fit well, 
model assumptions were met, and there were no multicol-
linearity problems. A significant regression equation was 
found [F(5, 89) = 3.054, p = 0.01], with an  R2 of 0.146. The 
perception of pharmacists is equal to 2.799 + 0.298 (Eth-
nicity1), where [Ethnicity1] is coded as 0 = Malay, 1 = Chi-
nese, 0 = Indian, 0 = Others. Chinese pharmacists had more 
positive perceptions compared to Malay pharmacists about 
patients with mental disorders, and about mental illness 
(p = 0.02). Respondents were neutral with regard to their 
confidence level and responsibility in managing mental dis-
orders (Table 5). General linear regression found no signifi-
cant relationship between level of comfort and the independ-
ent variables.
Perceived Barriers in Providing Pharmaceutical Care 
to Patients with Mental Disorders
According to rankings based on RIWF, the most frequently 
cited barrier was the lack of knowledge about mental disor-
ders. Others included patients’ lack of understanding about 
PC and legal requirements (Table 6). There were 43 open-
ended comments with regard to what would facilitate the 
provision of PC to patients with mental disorders, where 
23.3% of respondents mentioned the need for training not 
just with regard to mental disorders, but also counseling 
and PC. Four commented about the importance of having 
details on the patient history, while two mentioned the need 
for dispensing separation, collaboration between doctors and 
pharmacists, and social awareness to break the stigma.
Discussion
Our survey has attempted to determine the involvement 
of CPs in providing PC to patients with mental disorders. 
Our findings suggest that while CPs agree they have a role 
in managing mental disorders in the community, there are 
barriers to providing this, the main one being their lack of 
knowledge. Indeed, only slightly more than 30% of respond-
ents stated that they have a good understandingof mental dis-
orders. This should be expected since many seldom handled 
prescriptions on psychotropic medications, and therefore 
were less likely to be exposed to such patients. Approxi-
mately 30% of pharmacies also do not stock psychotropics.
Stocking and Pharmaceutical Care Services
Strict regulations of record keeping was one of the main 
reasons for not stocking psychotropics. A report by the Inter-
national Narcotics Control Board involving 102 countries 
found that the stocking of such substances were discour-
aged due to the strict restrictions regarding the dispensing 
protocol, and the time it consumed (International Narcotics 
Control Board 2016). Similarly in Saudi Arabia a survey 
showed that the commonly prescribed psychotropic drugs 
were unavailable in more than half of the 248 community 
pharmacies studied due the strict regulations for purchasing 
and dispensing psychotropics imposed by the government 
(Al-Ruthia et al. 2017).
Table 2  Reasons for not stocking psychotropics (n = 29)
Statement Disagree, N (%) Neither agree nor 
disagree, N (%)
Agree, N (%)
(a) Because mentally ill patients have unpredictable behaviour and are aggressive; and as 
such I’d rather not deal with them
11 (37.9) 8 (27.6) 10 (34.5)
(b) I fear for my life and as a result I’d rather not deal with these patients 16 (55.2) 7 (24.1) 6 (20.7)
(c) Fear of social drug-related complications 9 (31.0) 10 (34.5) 10 (34.5)
(d) I feel uncomfortable stocking psychiatric medications for fear of being robbed (n = 28) 15 (53.6) 7 (25.0) 6 (21.4)
(e) Numerous medical legal issues 3 (10.3) 6 (20.7) 20 (69.0)
(f) Tough regulations of record keeping as required by law 4 (13.8) 4 (13.8) 21 (72.4)
(g) Unfamiliar with psychotropics 12 (41.4) 11 (37.9) 6 (20.7)
(h) Unfamiliar with mental disorders 5 (17.2) 13 (44.8) 11 (37.9)
(i) Few requests (n = 28) 3 (10.7) 8 (28.6) 17 (60.7)
(j) Determined by parent company/boss/manager (n = 28) 7 (25.0) 11 (39.3) 10 (35.7)
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Table 3  Stocking and 
pharmaceutical care services 
(n = 96)
Statement N (%)
Frequency of prescription requests for psychotropics
 Daily 2 (2.1)
 Two to three times 7 (7.3)
 Once a week 22 (22.9)
 Once a month 22 (22.9)
 Once in 3–6 months 28 (29.2)
 Once a year 7 (7.3)
 Never 8 (8.3)
Gender of the majority of patients with prescription requests for psychotropics
 Male 31 (32.3)
 Female 15 (15.6)
 Equal 30(31.3)
Age group of the majority of patients with prescription requests for psychotropics
 18–29 3 (3.1)
 30–39 12 (12.5)
 40–49 30 (31.3)
 50–59 25 (26.0)
 60–69 16 (16.7)
 70–79 1 (1.0)
Average number of psychotropics sold a month (n = 61)
 0 26 (42.6)
 1 7 (11.5)
 2 5 (8.2)
 3 11 (18.0)
 4 1 (1.6)
 5 6 (9.8)
 > 5 5 (8.2)
Pharmaceutical care services provided to patients with mental  disordersa
 Counseling 58 (60.4)
 Dispensing of drugs 45 (46.9)
 Provision of drug information 37 (38.5)
 Monitoring for side effects 16 (16.7)
 Monitoring for adherence 10 (10.4)
 Solving drug-related problems 12 (12.5)
 None 24 (25.0)
 Monitoring of efficacy 7 (7.3)
Frequency of providing drug counseling to patients, or relatives of patients with mental disorders
 Daily 1 (1.0)
 Two to three times 4 (4.2)
 Once a week 8 (8.3)
 Once a month 22 (22.9)
 Once in 3–6 months 34 (35.4)
 Never 27 (28.1)
Psychotropics being stocked (n = 719)
 Antidepressants
  SSRIs 139 (19.3)
  TCAs 69 (9.6)
  SNRIs 30 (4.2)
  Others 98 (13.6)
 Antipsychotics
  Atypicals 107 (14.9)
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Table 3  (continued) Statement N (%)
  Typicals 48 (6.8)
 Anxiolytic
  Benzodiazepines 30 (4.2)
  Others 40 (5.6)
 Drugs for bipolar disorder/antimanicb 146 (20.3)
SSRI selective serotonin reuptake inhibitor, TCA tricyclic antidepressant, SNRI serotonin–norepinephrine 
reuptake inhibitors, MAOI monoamine oxidase inhibitors
a Respondents were allowed to select more than one response, therefore the sum may not always be 100%
b Includes antiepileptics and lithium
Table 4  Perception of pharmacists on patients with mental disorders and mental illness
Statement Mean (± SD) Disagree, N (%) Neither agree 
nor disagree, 
N (%)
Agree, N (%)
(a) I find patients with mental disorders easily approachable (n = 95) 2.78 (0.84) 33 (34.7) 45 (47.4) 17 (17.9)
(b) Handling of patients with mental disorders is easier compared to patients 
with other diseases (n = 94)
2.46 (0.77) 51 (54.3) 35 (37.2) 8 (8.5)
(c) Mental illness is nothing to be ashamed of (n = 94) 4.04 (0.83) 6 (6.4) 12 (12.8) 76 (80.9)
(d) All patients with mental disorders are potentially dangerous to the people 
around them (n = 95)
3.26 (0.93) 42 (44.2) 29 (30.5) 24 (25.3)
(e) I am not afraid of patients with mental disorders (n = 93) 3.22 (0.81) 18 (19.4) 38 (40.9) 37 (39.8)
(f) Patients with mental disorders do not want to talk to a pharmacist about 
their mental health symptoms (n = 95)
2.99 (0.88) 28 (29.5) 37 (38.9) 30 (31.6)
Table 5  Level of comfort of pharmacists in managing mental disorders
Statement Mean (± SD) Disagree, N (%) Neither agree 
nor disagree, 
N (%)
Agree, N (%)
(a) I find it easy to deal with relapse and non-adherence in patients with 
mental disorders (n = 95)
2.57 (0.79) 41 (43.2) 45 (47.4) 9 (9.5)
(b) I have an interest in providing pharmaceutical care to patients with men-
tal disorders (n = 94)
3.30 (0.84) 17 (18.1) 35 (37.2) 42 (44.7)
(c) I have enough knowledge on the pharmacotherapy of patients with mental 
disorders (n = 94)
2.78 (0.81) 34 (36.2) 44 (46.8) 16 (17.0)
(d) I feel confident enough to provide pharmaceutical care to patients with 
mental health problems (n = 93)
3.19 (0.89) 19 (20.4) 38 (40.9) 36 (38.7)
(e) I feel comfortable enough to provide pharmaceutical care to patients with 
mental health problems (n = 94)
3.35 (0.92) 18 (19.1) 27 (28.7) 49 (52.1)
(f) There is enough motivation for me to provide pharmaceutical care to 
patients with mental disorders (n = 95)
3.16 (0.90) 22 (23.2) 40 (42.1) 33 (34.7)
(g) I feel comfortable asking patients their reason(s) for using psychotropics 
(n = 95)
3.43 (0.81) 15 (15.8) 28 (29.5) 52 (54.7)
(h) I feel comfortable discussing the symptoms of mental illness with 
patients (n = 95)
3.37 (0.89) 16 (16.8) 29 (30.5) 50 (52.6)
(i) I received adequate education/training about mental health during my 
undergraduate pharmacy education (n = 95)
2.83 (1.01) 38 (40.0) 30 (31.6) 27 (28.4)
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The low frequency of prescription requests is another 
contributing factor, where close to 30% of the respondents 
revealed that they had never dispensed psychotropics before. 
This is because the community pharmacy is often regarded 
as being placed in the primary care setting, with the phar-
macist perceived as playing a peripheral as opposed to a 
central role, in the healthcare system (Crump et al. 2011). 
In Malaysia the majority of patients seek treatment at gov-
ernment hospitals, which are provided free of charge or at 
minimal cost, and only purchase psychotropics at commu-
nity pharmacies when government hospitals are out of stock 
or do not stock the psychotropics prescribed, similar to that 
observed in Ghana (Owusu-Daaku et al. 2010). The absence 
of dispensing separation in Malaysia is also a possible factor 
for low requests (Shafie et al. 2012), as most medications are 
dispensed from government and private hospitals and clin-
ics. As a result, most community pharmacies rarely receive 
prescriptions (Nik et al. 2016; Shafie et al. 2012).
It is encouraging to find out that the majority of respond-
ents agreed that there is a role for CPs in mental health care. 
This mirrored findings in the United States (US) and Can-
ada, where CPs demonstrated positive attitudes toward treat-
ing patients with mental disorders (Guillaumie et al. 2015; 
Watkins et al. 2017). In a roundtable discussion organized 
by the Royal Pharmaceutical Society in the United Kingdom 
(UK) to discuss how pharmacists can support patients with 
mental health issues, pharmacists expressed excitement in 
getting more involved in the care of this subset of patients. It 
was also highlighted that CPs have a significant role to play 
in the early identification of people with mental disorders, 
as well as in improving the physical health and adherence 
rates of these patients (Royal Pharmaceutical Society 2018).
While 60% of respondents reported providing counseling 
to patients, the majority reported low frequency of provid-
ing these services. This could be due to the low frequency 
of prescription requests. Additionally, less than 20% of 
respondents reported monitoring for side effects, efficacy, 
and adherence. As previously mentioned, nonadherence is a 
significant issue in this population (Higashi et al. 2013; Ho 
et al. 2015), with side effects cited as a main factor (De Las 
Cuevas et al. 2014; Hung et al. 2011). There is, however, a 
misconception on the part of health professionals that the 
newer generation drugs are void of side effects, thus scant 
attention is paid to this (Lingam and Scott 2002; Pampallona 
et al. 2002).
Perception and Level of Comfort of Pharmacists 
in Managing Mental Disorders
Since Malaysia is a multiracial country, it provided us with 
the opportunity to look at how different races respond to 
this issue. Chinese pharmacists had significantly more 
positive perceptions compared to Malay pharmacists about 
patients with mental disorders, and about mental illness. It 
has indeed been found that Malays are more likely to reject 
mental illness as they believe the condition is caused by 
supernatural forces (Hanafiah and Van Bortel 2015), mak-
ing them more predisposed to seeking spiritual and religious 
Table 6  Barriers to providing pharmaceutical care to patients with mental disorders in community pharmacy
Statement Disagree, N (%) Neither agree 
nor disagree, 
N (%)
Agree, N (%) RIWF Rank
(a) Lack of knowledge about mental disorders (n = 92) 23 (25.0) 24 (26.1) 45 (48.9) 0.692 1
(b) Patients do not understand pharmaceutical care (n = 93) 8 (8.6) 28 (30.1) 57 (61.3) 0.690 2
(c) Lack of training in pharmaceutical care practice (n = 92) 13 (14.1) 28 (30.4) 51 (53.1) 0.660 6
(d) Insufficient staff (n = 89) 20 (22.5) 23 (25.8) 46 (51.7) 0.613 8
(e) Lack of communication skills (n = 92) 39 (42.4) 31 (33.7) 22 (23.9) 0.542 14
(f) Lack of drug information sources (n = 90) 45 (50.0) 25 (27.8) 20 (22.2) 0.504 16
(g) Lack of documentation skills (n = 92) 30 (32.6) 34 (37.0) 28 (30.4) 0.571 13
(h) Lack of demand from patients (n = 92) 14 (15.2) 26 (28.3) 52 (56.5) 0.671 5
(i) Lack of private space/counseling area (n = 90) 27 (30.0) 22 (24.4) 41 (45.6) 0.598 11
(j) Lack of encouragement from head office/manager (n = 91) 27 (29.7) 39 (42.9) 25 (27.5) 0.541 15
(k) Lack of initiative (n = 92) 22 (23.9) 39 (42.4) 31 (33.7) 0.604 10
(l) Legal requirements (n = 92) 15 (16.3) 24 (26.1) 53 (57.6) 0.685 3
(m) Fear or discomfort of dealing with psychiatric patients (n = 91) 30 (33.0) 28 (30.8) 33 (36.3) 0.579 12
(n) Patient factors associated with their symptoms e.g. cognitive dysfunction, 
hostility, inattentiveness, irritability (n = 92)
20 (21.7) 38 (41.3) 34 (37.0) 0.606 9
(o) Time constraints (n = 92) 21 (22.8) 20 (21.7) 51 (55.4) 0.646 7
(p) Lack of patient information e.g. drug indication, treatment goals, etc. 
(n = 92)
14 (15.2) 22 (23.9) 56 (60.9) 0.675 4
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therapies (Khan et al. 2010). Subsequently, we found that the 
majority were quite neutral with regard to their confidence 
level and responsibility in managing patients with mental 
disorders. This is not an encouraging trend if PC services to 
patients with mental disorders are to be provided.
Perceived Barriers in Providing Pharmaceutical Care 
to Patients with Mental Disorders
Lack of knowledge about mental disorders was ranked as 
the main barrier, which corresponds with the findings where 
close to 60% of the respondents rated their knowledge of 
mental disorders as ‘fair’ or ‘poor’. This corroborates with 
studies involving CPs in Australia, Canada, Ghana, Belgium, 
the UK, and the US, who have cited their low confidence and 
discomfort due to their lack of training, education, and clini-
cal skills in mental disorders; as barriers to them monitoring 
patients, identifying drug-related problems, and discussing 
symptoms of mental disorders as well as drug-related issues 
with patients (Cates et al. 2005; Liekens et al. 2012a, b; 
Maslen et al. 1996; O’Reilly et al. 2015; Owusu-Daaku et al. 
2010; Phokeo et al. 2004; Watkins et al. 2017).
A large number of respondents agreed that patients do not 
understand the concept of PC, mirroring findings from the 
Middle-East, Asia, and rural areas in the UK, which found 
that the majority of consumers have a negative view of CPs, 
perceiving them to be more business-centric, and declaring 
that their primary role is to dispense medication (Awad et al. 
2017; Merks et al. 2016). Indeed very few are aware of the 
expanded roles of CPs such as in providing PC services and 
managing chronic diseases (Hasan et al. 2015; Merks et al. 
2016; Erah and Chuks-Eboka 2008; You et al. 2011), and 
still defer to doctors as the primary expert on drug-related 
matters (Awad et al. 2017; Hallak 2012). It is postulated 
that in these countries, similar with Malaysia, consumers 
are more comfortable with the traditionally-defined roles 
of healthcare professionals in the healthcare system, where 
doctors are held in high-esteem on all health-related mat-
ters. This then leads them to reject the clinical roles of 
pharmacists. Additionally, as patients usually receive their 
prescribed medications from doctors, they are unaware of 
pharmacists’ roles beyond dispensing medication (You et al. 
2011).
Implications for Future Training, Policy and Practice
The World Health Organization (WHO) has highlighted 
that CPs should provide PC services to patients (World 
Health Organization 1994). CPs are the most accessible 
healthcare professionals due to their proximity to patients, 
and subsequently the high volume of customers who fre-
quent their pharmacies (Awad et al. 2017; Rubio-Valera 
et al. 2014; World Health Organization 1994). Pharmacists 
have also expressed a desire to expand their roles beyond 
dispensing, and have made the move to engage in more 
clinically-oriented roles (Luetsch 2017; Murphy et  al. 
2016a), while patients have expressed that they find phar-
macists more approachable and accessible than doctors 
(Deslandes et al. 2015). CPs are in the perfect position to 
screen for depression, provide counseling, monitor and 
encourage adherence, and monitor the outcomes of phar-
macotherapy (Rubio-Valera et al. 2014). Findings from 
this study, however, indicate that there are a few barriers to 
CPs providing PC services to these patients, such as gaps 
in knowledge and training, the lack of public knowledge 
on PC services, and the influence of culture and stigma.
CPs have requested more education and training pro-
grams in mental health, such as training in psychosocial 
communication(Liekens et al. 2012a, b), or regular work-
shops to educate them on counseling, therapeutics, and 
signs and symptoms of mental disorders (Owusu-Daaku 
et al. 2010). It was indeed found that CPs who attended 
continuing education courses on mental disorders were 
more confident in interacting with these patients (Maslen 
et al. 1996), and the quality of pharmacist–patient inter-
actions was improved (Liekens et al. 2014). Additionally, 
there is a need for mental health education modules to 
adopt methods which will reduce stigma, instead of solely 
focusing on the science and therapeutic aspects of the dis-
eases (Murphy et al. 2016b; Rubio-Valera et al. 2014). 
Incorporating Mental Health First Aid (MHFA) training in 
pharmacists’ training is also proposed (Kirschbaum et al. 
2016).
Approximately 60% of respondents agreed that mem-
bers of the community are also ignorant about the clinical 
role of CPs, and one reason for this could be the lack of 
dispensing separation. This has also led to the lack of pre-
scriptions received, leading to minimal to zero interactions 
between CPs and patients with mental disorders, curbing 
their opportunity to learn on the job and enhance their 
psychosocial communication skills. More importantly, this 
has denied CPs the chance to provide PC services. Dis-
pensing separation is practiced in many Western countries 
and has proven to be effective in preventing over-prescrib-
ing, minimizing prescription errors or misuse of medi-
cation, as well as reducing health-related costs (Salmasi 
et al. 2016). A strong opposition to this separation was the 
lack of pharmacists, however it is estimated that Malay-
sia will soon reach the pharmacist-to-population ratio as 
recommended by the WHO (Shafie et al. 2012). Patients 
themselves acknowledge pharmacists as drug experts—
viewing them as more suitable to dispense compared to 
doctors, and willing to pay for their services (Shafie and 
Hassali 2010). It is thus, time for Malaysia to adopt dis-
pensing separation to ensure the optimum care of these 
patients in the community.
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Limitations and Strengths
Our study had a number of limitations such as recall bias 
especially on questions related to the number and type of 
patients. Given the low response rate of 36.8%, findings 
might not be representative of the perceptions of all CPs 
in Peninsular Malaysia. However, the number of responses 
was greater than the 88 required. In addition, based on 
previously conducted nationwide studies of CPs in Malay-
sia, the demographics of respondents in our survey seem 
to be a fairly representative sample of CPs in Malaysia, 
where the majority are Chinese, female, and between 31 
and 40 years of age (Chong et al. 2010; Khan et al. 2016; 
Siang et al. 2008). Other than that, as the question on the 
stocking of psychotropics was the first question, the major-
ity of CPs might have chosen not to respond to the rest 
of the questions as they did not stock any psychotropics, 
assuming the survey was not relevant to them.
Conclusions
Many CPs are positive toward their involvement in mental 
healthcare. The main barrier to providing PC, however, is 
the lack of knowledge. About a quarter of the respondents 
claimed that they did not stock any psychotropics due to 
legal issues and minimal prescription requests. Findings 
can be used by the relevant healthcare authorities in the 
design and implementation of programs and workshops 
targeted toward training CPs. This will hopefully encour-
age more community pharmacies to sell psychotropics and 
provide PC to this subset of patients, which will subse-
quently result in patients who are able to function in soci-
ety and contribute to the economy.
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